Main menu

Recent Pfizer Press Releases

2/3/15 6:00pm EST
Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib)

 

First Cyclin-Dependent Kinase 4/6 (CDK 4/6) Inhibitor Approved by the FDA 
- - - 
IBRANCE Now Available for Use in Combination with Letrozole as First-Line Treatment of Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer

Pfizer Inc. today announced the U.S.

more...
1/27/15 7:00am EST
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

more...
1/26/15 4:12pm EST
Pfizer Commits to Further Reduce Price for Prevenar 13 in the World’s Poorest Countries Through 2025

Pfizer Announces New Commitments During Gavi’s Pledging Conference

Pfizer Inc. (NYSE:PFE) today announced new commitments aimed at ensuring the world’s most resource-limited countries have access to Prevenar 13* (pneumococcal polysaccharide conjugate vaccine (PCV), 13 – valent, absorbed) through Gavi, the Vaccine Alliance. Pfizer’s commitments were announced during Gavi’s pledging conference being held in Berlin, Germany, in support of Gavi’s 2016 – 2020 strategy.

more...
1/21/15 6:45am EST
Pfizer and the Avon Foundation for Women Award 23 Grants Totaling $1 Million in Funding to Support Patients Living With Metastatic Breast Cancer

Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify.

more...
1/8/15 8:30am EST
Pfizer Provides Update on IBRANCE® (palbociclib)

The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc.

more...
1/5/15 7:30am EST
Pfizer Acquires Redvax GmbH

Acquisition Provides Pfizer with a Preclinical CMV Vaccine Candidate

Pfizer Inc. today announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

more...

Pages